[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07698314":3,"trial-entities:NCT07698314":96,"trial-summary:NCT07698314":100},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":21,"study_type":22,"primary_purpose":14,"phases":23,"enrollment_info":25,"interventions":28,"primary_outcomes":45,"secondary_outcomes":58,"sex":59,"minimum_age":60,"maximum_age":61,"healthy_volunteers":62,"eligibility_criteria":63,"std_ages":67,"locations":70,"central_contacts":86,"overall_officials":89,"references":94,"see_also_links":95},"NCT07698314","2026-125","A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer","Myo-EXERTBC: A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer","NOT_YET_RECRUITING","2028-06","2026-07","2026-07-13","2026-06","Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","OTHER",true,"In this pilot study, the investigators will assess the changes in myokine production based on several different exercise regimens.",null,[19,20],"Cancer","Breast Cancer",[],"INTERVENTIONAL",[24],"NA",{"count":26,"type":27},21,"ESTIMATED",[29,35,40],{"type":30,"name":31,"description":32,"armGroupLabels":33},"BEHAVIORAL","Conditioning Resistance Training","Participants in this group will perform a conditioning regimen from the EXERT-BCHC protocol, specifically described as \"double training\".",[34],"Conditioning Regimen Group",{"type":30,"name":36,"description":37,"armGroupLabels":38},"Strength Resistance Training","Participants in this group will perform a strength regimen from the EXERT-BCHC protocol, specifically described as \"8x8\".",[39],"Strength Regimen Group",{"type":30,"name":41,"description":42,"armGroupLabels":43},"Hypertrophy Resistance Training","Participants in this group will perform a hypertrophy regimen from the EXERT-BCHC protocol, specifically described as the \"control arm\".",[44],"Hypertrophy Regimen Group",[46,50,54],{"measure":47,"description":48,"timeFrame":49},"Change in Myokine Production After First Exercise Session","Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples. The change from pre-exercise to post-exercise levels will be determined.","Immediately before and immediately after the first exercise session.",{"measure":51,"description":52,"timeFrame":53},"Change in Myokine Production After Final Exercise Session of Each Week","Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples for each group. The change from pre-exercise to post-exercise levels at the end of each week will be determined.","Immediately before and immediately after the final exercise session of weeks 1, 2, 3, and 4.",{"measure":55,"description":56,"timeFrame":57},"Change in Myokine Production After Final Exercise Session of the Month (End of Study)","Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples for each group. The change from pre-exercise to post-exercise levels at the culmination of the 4-week exercise period will be determined.","Immediately before and immediately after the final exercise session of week 4 (end of the 4-week exercise regimen).",[],"FEMALE","20 Years","89 Years",false,{"inclusion":64,"exclusion":65,"raw_text":66},[],[],"Inclusion Criteria:\n\n1. Age 20-89 years\n2. Women prescribed exercise as a SOC\n3. Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast\n4. Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.\n5. Women with \\> 3 months of resistance training experience under expert guidance at the Allegheny Health Network Exercise Oncology Center\n\nExclusion Criteria:\n\n1. Any current treatment with cytotoxic chemotherapy for breast cancer\n2. Inability to safely engage in group sessions of resistance training as deemed by study PI\n3. Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training\n4. Pregnant women\n5. Males",[68,69],"ADULT","OLDER_ADULT",[71],{"facility":72,"city":73,"state":74,"zip":75,"country":76,"contacts":77,"geoPoint":83},"AHN Allegheny General Hospital","Pittsburgh","Pennsylvania","15212","United States",[78],{"name":79,"role":80,"phone":81,"email":82},"Clinical Trials Contact","CONTACT","412-330-6151","clinicaltrials@ahn.org",{"lat":84,"lon":85},40.44062,-79.99589,[87],{"name":79,"role":80,"phone":81,"email":88},"ctgov@ahn.org",[90],{"name":91,"affiliation":92,"role":93},"Colin Champ, MD","AHN Radiation Oncology","PRINCIPAL_INVESTIGATOR",[],[],{"nct_id":4,"conditions":97,"biomarkers":99},[98],"Breast Carcinoma",[],{"nct_id":4,"found":15,"summary":101,"prompt_version":111},{"design":102,"status":103,"heading":104,"summary":105,"follow_up":106,"word_count":107,"commitments":108,"compensation":109,"drugs_mentioned":110},"This is an interventional pilot study with a planned enrollment of 21 women. It is not specified if the study is randomized or blinded.","completed","Pilot Study on Exercise Regimens After Breast Cancer Treatment","This pilot study is looking at how different exercise programs affect \"myokines\" (proteins released by muscles during exercise) in women who have completed breast cancer treatment. You could participate if you are a woman between 20 and 89 years old, have been diagnosed with breast cancer (ductal carcinoma in situ or invasive carcinoma), and have received treatment like surgery, radiation, chemotherapy, immunotherapy, or hormonal therapy. The study is testing three types of exercise: Conditioning Resistance Training, Strength Resistance Training, and Hypertrophy Resistance Training. Researchers will measure myokine levels before and after exercise sessions to see how they change. The goal is to understand how exercise impacts these proteins after breast cancer treatment. The current status of this study is unclear.","Myokine production will be measured immediately before and after the first exercise session, after the final exercise session of each week (weeks 1, 2, 3, and 4), and after the final exercise session of week 4 (end of the 4-week exercise regimen).",120,"You would participate in one of three exercise regimens. Myokine production will be measured before and after exercise sessions over a four-week period.","Not stated in the trial record.",[31,36,41],"v2"]